KCNJ11 and neonatal diabetes mellitus: Identifying KCNJ11 and ABCC8 mutations has significantly advanced our understanding of NDM and enabled the development of targeted therapies, particularly sulfonylureas, which have greatly improved glycemic control and reduced the need for insulin injections [9].